RESUMO
Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners, surgeons, oncologists, and other health care professionals giving care to patients with solid tumours.
Assuntos
Biomarcadores Tumorais , Neoplasias , Administração dos Cuidados ao Paciente , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/classificação , Humanos , Neoplasias/sangue , Neoplasias/classificação , Neoplasias/diagnóstico , Neoplasias/terapia , Administração dos Cuidados ao Paciente/métodos , Administração dos Cuidados ao Paciente/normas , Guias de Prática Clínica como AssuntoRESUMO
Analysis of masticatory function is the basis of clinical work in almost all fields of dentistry. Bite forces are the expression and measure of masticatory function. Physical training has an effect on the development of functional ability, motoric ability of the organism and the formation of desired physical proportions. The purpose of this study was to examine the association between physical fitness and bite force values. Because of strictly defined regulations in the army with regard to training and nutrition, Croatian Army recruits were ideal examinees for this examination. The examinees were 135 recruits. Bite forces were measured on three places (area of the central incisors, left and right in the area of the first molars) before and after three-months of training. Of all the examinees, 108 had increased their body weight, 12 had decreased it and 15 had not changed their body weight. The median of measured forces in the recruits prior to training was 291 N in the right (lateral quadrant), 285.5 N in the left lateral quadrant and 205 N in the anterior area. After training the median of measured forces in the right quadrant was 312 N, in the left 313 N and in the anterior area 216 N Greater bite forces after training on all measured places were statistically proved. Increased activity of masticatory muscles can have the same effect on the values of bite forces as bite training. There are few data on the correlation between physical muscles and values of bite forces. The results of those studies are doubtful. In this study, after three months of conditional training, the body mass of the recruits had increased and they expressed greater values of bite forces. However, correlation between body mass and bite forces cannot be proved with certainty.
Assuntos
Força de Mordida , Peso Corporal/fisiologia , Músculos da Mastigação/fisiologia , Militares , Aptidão Física/fisiologia , Adolescente , Adulto , Humanos , Incisivo/fisiologia , Masculino , Dente Molar/fisiologia , Adulto JovemRESUMO
We retrospectively investigated clinical and prognostic significance of psoas muscle index (PMI) calculated as total psoas muscle area at L3 vertebra level obtained from baseline computed tomography (CT) scans in 49 newly diagnosed classical Hodgkin's lymphoma (cHL) patients prior to specific treatment. Median PMI was 572.5â¯mm2/m2 and was significantly higher in males (Pâ¯<â¯0.001), patients with higher body mass index (BMI, Pâ¯<â¯0.001), absence of extranodal disease (Pâ¯= 0.037), higher absolute lymphocyte count (Pâ¯= 0.037), higher hemoglobin (Pâ¯= 0.010) and lower lactate dehydrogenase (LDH, Pâ¯= 0.050). There were no significant associations with age, disease subtype, presence of constitutional symptoms, Ann Arbor disease stage, presence of advanced disease or international prognostic score. Patients with lower PMI had significantly worse PFS (hazard ratio [HR] 4.91; Pâ¯= 0.009). This phenomenon persisted in the multivariate model (HRâ¯= 5.09; Pâ¯= 0.042) adjusted for International Prognostic Score (IPS) and chemotherapy type.
Assuntos
Doença de Hodgkin , Músculos Psoas , Doença de Hodgkin/diagnóstico por imagem , Doença de Hodgkin/tratamento farmacológico , Humanos , Masculino , Prognóstico , Modelos de Riscos Proporcionais , Músculos Psoas/diagnóstico por imagem , Estudos RetrospectivosRESUMO
High incidence of venous thromboembolic (VTE) events in coronavirus disease 2019 (COVID-19) patients has been reported despite pharmacologic thromboprophylaxis. We performed prospective bilateral lower extremity ultrasound evaluation of prolonged hospitalized COVID-19 ward patients from our institution without clinical suspicion of deep vein thrombosis (DVT).A total of 102 patient were included in the study. All patients were receiving pharmacologic thromboprophylaxis, the majority in intermediate or therapeutic doses. Asymptomatic DVT was detected in 26/102 (25.5%) patients: 22 had distal and four had proximal DVT, six had bilateral leg involvement. Pulmonary embolism was highly prevalent (17/70, 24.3%) but similarly grouped among patients with and without asymptomatic DVT. In total 37.2% of patients included in the study were recognized as having VTE.Asymptomatic DVT events were more common in intensive care unit (ICU) survivors (60% in postmechanically ventilated ICU survivors, 21.2% in ward patients, 22% in high-flow oxygen treated patients; Pâ¯= 0.031), in patients with higher modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE risk-score (median 3 vs. 2 points with and without DVT; Pâ¯= 0.021) and higher body temperature on admission (median 38.7⯰C vs. 37.7⯰C with and without DVT; Pâ¯= 0.001). No clear associations with Padua VTE risk score, demographic and other clinical characteristics, intensity of thromboprophylaxis, severity of other COVID-19 symptoms, degree of systemic inflammation or Ddimers on admission were found (Pâ¯> 0.05 for all analyses).Systematic ultrasound assessment in prolonged hospitalized severe COVID-19 patients prior to hospital discharge is needed, especially in ICU survivors, to timely recognize and appropriately treat patients with asymptomatic DVT.
Assuntos
COVID-19 , Tromboembolia Venosa , Trombose Venosa , Anticoagulantes , Humanos , Estudos Prospectivos , SARS-CoV-2 , Trombose Venosa/diagnóstico por imagem , Trombose Venosa/epidemiologiaRESUMO
This study retrospectively analyzed glioma-associated oncogene 1 (GLI1) mRNA expression in unfractionated bone marrow aspirates of 32 patients with myelofibrosis and 16 controls. It was found that GLI1 expression did not significantly differ between primary, secondary myelofibrosis and controls (median difference in threshold cycles ∆CT 7.2, 7.3 and 6.9, respectively; Pâ¯= 0.864), as well as that survival curves of myelofibrosis patients with higher/lower GLI1 expression showed multiple overlaps and overall comparable course (Pâ¯= 0.651). The results suggest that general upregulation of GLI1 does not seem to be a feature of the disease and are in line with modest biological and clinical effects observed with inhibitors of Hedgehog signaling pathway in patients with myelofibrosis.
Assuntos
Glioma , Mielofibrose Primária , Proteínas Hedgehog , Humanos , Mielofibrose Primária/genética , Estudos Retrospectivos , Transdução de SinaisRESUMO
First obinutuzumab application is associated with infusion related reactions (IRRs) that may discourage further continuation of the drug. During our clinical practice we have observed that chronic lymphocytic leukemia (CLL) patients with autoimmune hemolytic anemia (AIHA) prolongedly receiving corticosteroids do not develop obinutuzumab IRRs. Therefore, we decided to apply prolonged corticosteroid premedication with methylprednisolone in dose 1-1.5 mg/kg for ≥7 days to all further obinutuzumab candidates. Here we present non-randomized comparison of 28 consecutive previously untreated CLL patients receiving prolonged corticosteroid premedication (15 patients) or standard premedication (13 patients) prior to the first obinutuzumab infusion. Prolonged corticosteroid premedication resulted in significant reduction of all-grade (20% vs 61.5%; p = .025) and grade III (0% vs 23.1%; p = .049) obinutuzumab IRRs. Prolonged corticosteroid premedication did not significantly affect occurrence of infective complications. Patients with CLL and AIHA receiving obinutuzumab showed continuous and stable increase in hemoglobin levels concomitantly with decrease in parameters of hemolysis.